Jena Shaw Tronieri, Ph.D.

Jena Shaw ronieri, Ph.D.

University of Pennsylvania Perelman School of Medicine, 3535 Market St., Suite 3025, Philadelphia, PA 19104-3309

jena.tronieri@pennmedicine.upenn.edu

(215) 898-7314

Jena Shaw Tronieri, Ph.D.  is a Senior Research Investigator at the Center for Weight and Eating Disorders in the Department of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania. She received her B.A. from Franklin and Marshall College, and her M.S. and Ph.D. in clinical psychology from Drexel University. She completed her pre-doctoral internship at Geisinger Medical Center.

Dr. Tronieri's research focuses on identifying individual predictors of weight loss success and improving weight loss treatment outcomes for patients with obesity. She is also interested in evaluating acceptance-based treatments for weight and eating disorders. Dr. Tronieri is currently involved in studies examining predictors of bariatric surgery outcomes and clinical trials evaluating behavioral and pharmaceutical treatments for weight loss and for binge eating disorder.

In her clinical work, Dr. Tronieri provides behavioral weight control therapy in both individual and groups settings. She uses evidence-based treatments, including cognitive therapy and acceptance and commitment therapy, to treat patients with eating disorders and patients seeking weight loss who have comorbid anxiety or depression. She also serves as a supervisor to practicum students at CWED engaged in the treatment of these populations.

Recent publications include:

  • Tronieri JS, Ghanbari E, Chevinsky J, LaFata EM, Minnick AM, Rajpal S, Wang SY, Burcaw K, Berkowitz RI, Wadden TA. Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial. Nature Medicine. 2025;31(5):1653-1660. doi: 10.1038/s41591-025-03556-3.

  • Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, Leonard S, Jakicic JM. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Current Obesity Reports. 2023 ;12(4):453-473. doi: 10.1007/s13679-023-00534-z. 

  • Thaweethai T, Jolley SE, Karlson EW, et al.; RECOVER Consortium. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934-1946. doi: 10.1001/jama.2023.8823. 

  • Casiraghi E, Wong R, Hall M, Coleman B, Notaro M, Evans MD, Tronieri JS, Blau H, Laraway B, Callahan TJ, Chan LE, Bramante CT, Buse JB, Moffitt RA, Stürmer T, Johnson SG, Raymond Shao Y, Reese J, Robinson PN, Paccanaro A, Valentini G, Huling JD, Wilkins KJ; N3C Consortium. A method for comparing multiple imputation techniques: A case study on the U.S. national COVID cohort collaborative. J Biomed Inform. 2023;139:104295. doi: 10.1016/j.jbi.2023.104295. 

  • Tronieri JS, Wadden TA, Walsh O, Berkowitz RI, Alamuddin N, Gruber K, Leonard S, Bakizada ZM, Chao AM. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. International Journal of Obesity. 2019 Mar 29:1. DOI: 10.1038/s41366-019-0348-6


Back to Top